Related Experiment Video
Updated: May 9, 2025
07:47
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
Published on: October 29, 2019
18.2K
Oligonucleotide therapeutics for neurodegenerative diseases
1University High School, Irvine, CA, USA.
Neuroimmune Pharmacology and Therapeutics
|May 1, 2025
Summary
New oligonucleotide technologies, like nanoparticle delivery and C16-conjugation, are enabling small interfering RNA (siRNA) and antisense oligonucleotide (ASO) therapies for neurodegenerative diseases. These advances target nerve tissues, offering hope for conditions like Alzheimer's disease.
Area of Science:
- Biotechnology
- Neuroscience
- Pharmacology
Background:
- Oligonucleotides, including small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), show promise for treating chronic diseases with limited options.
- Current delivery methods are effective for hepatic tissue but face challenges in reaching extrahepatic tissues, particularly nerve tissues.
Purpose of the Study:
- To review recent advancements in oligonucleotide delivery technologies.
- To explore the potential of these technologies for treating neurodegenerative diseases.
Main Methods:
- Review of nanoparticle delivery systems for oligonucleotides.
- Discussion of local administration strategies for enhanced tissue targeting.
- Analysis of 2'-O-hexadecyl (C16)-conjugation for improved oligonucleotide properties.
- Examination of clinical translation factors for neurodegenerative disease applications.
Main Results:
- Nanoparticle, local administration, and C16-conjugation methods show potential for extending oligonucleotide applicability to nerve tissues.
- These technologies can overcome delivery barriers for siRNA and ASO therapies in the central nervous system.
Conclusions:
- Advances in oligonucleotide delivery are crucial for developing new treatments for neurodegenerative diseases.
- Successful clinical translation requires addressing specific challenges related to modified or engineered oligonucleotides for neurological applications.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
01:15Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308
02:30siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
01:26Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315